Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements. The Impax Specialty Pharma segment focuses on the development, sale, and distribution through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson's disease, and post-herpetic neuralgia, as well as other select specialty segments. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals USA, Inc. to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.
Impax Laboratories (IPXL) shares were up Monday as a former Actavis Specialty Pharmaceuticals executive takes the helm at the company as president and CEO. Impax shares popped 38% Monday on news that the company hired Paul M. Bisaro, hitting $12.77 apiece midday. Officials at Impax, which makes a generic version of Adrenaclick, which is a competitor to EpiPen, said Bisaro will replace J. Kevin Buchi, who had been serving as interim CEO since December. https://www.thestreet.com/story/14060953/1/impax-gains-38-on-ceo-appointment-talk-of-sale.html
